Education
About Us
Working with TipRanks
Follow Us
Shilpa Medicare Limited (IN:SHILPAMED)
:SHILPAMED
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹501.60
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹62.57B
Enterprise Value₹69.80B
Total Cash (Recent Filing)₹285.24M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)41.7
Beta0.98
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)2.28
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.70
Price to Sales (P/S)4.98
P/FCF Ratio-57.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.9
Revenue Forecast (FY)₹14.68B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 68% gross margin signals durable pricing power from complex APIs and specialty formulations. High gross margins provide structural cushion to absorb SG&A and R&D, enabling reinvestment in regulated-market approvals and capacity for long-term growth despite operational cost pressures.
Improved Leverage & Robust Equity RatioLower leverage and a 71.7% equity ratio materially reduce financial risk and interest burden. This balance sheet strength gives the company enduring flexibility to fund capex, support CDMO contracts, and weather product development cycles without immediate refinancing pressure.
Sustained Revenue Growth And Oncology FocusDouble-digit revenue growth alongside a strategic focus on oncology and CDMO positions the company in structurally growing, higher-barrier segments. Specialized oncology APIs and contract manufacturing create recurring, sticky revenue and higher long-term margin potential versus commodity generics.
Bears Say
Negative Free Cash Flow From CapexSubstantial capex driving negative free cash flow reduces liquidity and limits internal funding for R&D or commercial expansion. If elevated capex persists, the company may need external financing or to curb investment, which could slow product launches and CDMO capacity scaling.
Worsening Operating MarginA sharp drop in EBIT margin signals rising operating costs or inefficiencies that undermine profitability despite strong gross margins. Persistent margin erosion would weaken cash generation, constrain reinvestment for regulated-market approvals, and impair long-term return profiles.
Low ROE And Modest Net MarginDespite stronger revenues, low ROE and single-digit net margins indicate limited returns on shareholders' equity. Over time, this can limit the company’s ability to self-finance growth and may signal that scale or cost structure improvements are required to deliver sustainable investor returns.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹501.60 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹62.57B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is May 21, 2026 which is in 83 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Feb 06, 2026. The company reported ₹2.28 earnings per share for the quarter, missing the consensus estimate of ₹2.8 by -₹0.52.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.16%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹2.28 in its last earnings report, missing expectations of ₹2.8. Following the earnings report the stock price went down -0.663%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―